The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-26 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
The Blue Book, formally titled Nomenclature of Organic Chemistry, is a collection of recommendations on organic chemical nomenclature. Updates are published at irregular intervals. A full edition was published in 1979, an abridged and updated version of which was published in 1993 as A Guide to IUPAC Nomenclature of Organic Compounds. Both of these are now out-of-print in their paper versions, but are available free of charge in electronic versions. After the release of a draft version for public comment in 2004 and the publication of several revised sections in the journal Pure and Applied Chemistry, a fully revised version was published in print in 2013.
=== Biological fluorescence === Chemical biologists often study the functions of biological macromolecules using fluorescence techniques. The advantage of fluorescence versus other techniques resides in its high sensitivity, non-invasiveness, safe detection, and ability to modulate the fluorescence signal. In recent years, the discovery of green fluorescent protein (GFP) by Roger Y. Tsien and others, hybrid systems and quantum dots have enabled assessing protein location and function more precisely. Three main types of fluorophores are used: small organic dyes, green fluorescent proteins, and quantum dots. Small organic dyes usually are less than 1 kDa, and have been modified to increase photostability and brightness, and reduce self-quenching. Quantum dots have very sharp wavelengths, high molar absorptivity and quantum yield. Both organic dyes and quantum dyes do not have the ability to recognize the protein of interest without the aid of antibodies, hence they must use immunolabeling. Fluorescent proteins are genetically encoded and can be fused to your protein of interest. Another genetic tagging technique is the tetracysteine biarsenical system, which requires modification of the targeted sequence that includes four cysteines, which binds membrane-permeable biarsenical molecules, the green and the red dyes "FlAsH" and "ReAsH", with picomolar affinity. Both fluorescent proteins and biarsenical tetracysteine can be expressed in live cells, but present major limitations in ectopic expression and might cause a loss of function.
=== Names === Amitriptyline is the English and French generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while amitriptyline hydrochloride is its USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name. Its generic name in Spanish and Italian and its DCITTooltip Denominazione Comune Italiana are amitriptilina, in German is Amitriptylin, and in Latin is amitriptylinum. The embonate salt is known as amitriptyline embonate, which is its BANM, or as amitriptyline pamoate unofficially. Other brand names include Elavil, Vanatrip, Endep and Tryptomer.
=== Nanoparticles === The most promising drug delivery system is using nanoparticle delivery systems, these are systems where the drug is bound to a nanoparticle capable of traversing the blood–brain barrier. The most promising compound for the nanoparticles is Human Serum Albumin (HSA). The main benefits of this is that particles made of HSA are well tolerated without serious side effects as well as the albumin functional groups can be utilized for surface modification that allows for specific cell uptake. These nanoparticles have been shown to transverse the blood–brain barrier carrying host drugs. To enhance the effectiveness of nanoparticles, scientists are attempting to coat the nanoparticles to make them more effective to cross the blood–brain barrier. Studies have shown that "the overcoating of the [nanoparticles] with polysorbate 80 yielded doxorubicin concentrations in the brain of up to 6 μg/g after i.v. injection of 5 mg/kg" as compared to no detectable increase in an injection of the drug alone or the uncoated nanoparticle. This is very new science and technology so the real effectiveness of this process has not been fully understood. However young the research is, the results are promising pointing to nanotechnology as the way forward in treating a variety of brain diseases.
Biological devolution or de-evolution is a misnomer, not only because it implies that organisms can only evolve backward or forward, but also because it implies that evolution may cause organisms to evolve in the "wrong" direction. The phrase "survival of the fittest" refers to biological fitness, not physical fitness. Biological fitness is the quantitative measure of individual reproductive success, e.g. the tendency of lineages containing individuals that produce more offspring in a particular environment to persist and thrive in that environment. Further, while the related concepts of "survival of the fittest" and "natural selection" are often used interchangeably, they are not the same: natural selection is not the only form of selection that determines biological fitness (see sexual selection, fecundity selection, viability selection, and artificial selection). Evolution does not "plan" to improve an organism's fitness to survive. This misconception is encouraged as it is common shorthand for biologists to speak of a purpose as a concise form of expression (sometimes called the "metaphor of purpose"); it is less cumbersome to say "Dinosaurs may have evolved feathers for courtship" than "Feathers may have been selected for when they arose as they gave dinosaurs a selective advantage during courtship over their non-feathered rivals". However, this can result in many students explaining evolution as an intentional and purposeful process. Mutations are not all equally likely, nor do they occur at the same frequency everywhere in the genome.
Sources: en.wikipedia.org
"Cold storage" simply means keeping the private keys out of reach of hackers by storing or generating them on a device that is not connected to the internet. The credentials necessary to spend crypto can be stored offline in a number of different ways, from simple paper printouts of private keys, to specialized hardware wallets.
== Promotion == In March 2006, it was announced that "Come What May," would be released on July 18, 2006. However, the release date for the album was pushed back until August 22. Because of the delay, Stone Sour released a music video for the track "Reborn", which had footage of the band working on the album in the studio. The album's cover artwork was released online on May 20, 2006. Shortly after, it was confirmed by a representative from the band's record label, Roadrunner, that the release date had been brought forward, and the official release date would be August 1, 2006. On July 31, 2006, the day before its release the album was made available online for streaming in its entirety through AOL. On May 22, 2006, the first single from the album, "30/30-150", was made available online as a free MP3 download. A music video for the single was shot with director P.R. Brown in Los Angeles and received a premier on MTV's Headbangers Ball on June 3, 2006. Prior to the release of the second single from the album, "Through Glass", radio stations throughout the US showed high support for the song. A music video for the single was shot with director Tony Petrossian and was released online on June 9, 2006, through Yahoo!. The third single from the album, "Sillyworld", began receiving radio airplay in November 2006. A music video for the single was shot in January 2007 and was released online on March 8, 2007. The fourth single from the album, "Made of Scars", had a music video which was recorded live on April 7, 2007, and was posted online on June 5, 2007.
Human uses of AGPs include the use of Gum arabic in the food and pharmaceutical industries because of natural properties in thickening and emulsification. AGPs in cereal grains have potential applications in biofortification, as sources of dietary fibre to support gut bacteria and protective agents against ethanol toxicity. Arabinogalactan Proteoglycan This article was adapted from the following source under a CC BY 4.0 license (2021) (reviewer reports): Yingxuan Ma; Kim Johnson (2021). "Arabinogalactan-proteins" (PDF). WikiJournal of Science. 4 (1): 2. doi:10.15347/wjs/2021.002. Wikidata Q99557488.
P. Saraswathy, A.C. Dey, S.K. Sarkar, C. Kothalkar, P. Naskar, G. Arjun, S.S. Arora, A.K. Kohli, V. Meera, V. Venugopal and N.Ramamoorthy (2007). "99mTc generators for clinical use based on zirconium molybdate gel and (n, gamma) produced 99 Mo: Indian experience in the development and deployment of indigenous technology and processing facilities" (PDF). Proceedings of the 2007 International RERTR Meeting.{{cite journal}}: CS1 maint: multiple names: authors list (link) Iturralde MP (1 December 1996). "Molybdenum-99 production in South Africa". European Journal of Nuclear Medicine. 23 (12): 1681–1687. doi:10.1007/BF01249633. S2CID 28154691. Hansell C (1 July 2008). "Nuclear Medicine's Double Hazard: Imperiled Treatment and the Risk of Terrorism" (PDF). The Nonproliferation Review. 15 (2): 185–208. doi:10.1080/10736700802117270. S2CID 8559456. Archived from the original (PDF) on 18 July 2013. Retrieved 24 May 2012.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。